The chimeric approach is applicable for rapid updating of immunogens, and our data supported the use of variant-adapted multivalent vaccine against circulating and emerging variants. Again, the chimeric vaccine elicited broader sera neutralization of SARS-CoV-2 variants and conferred better protection against challenge by either Delta or Omicron SARS-CoV-2 in mice. This approach was generalized to develop Delta-Omicron chimeric RBD-dimer to adapt the currently prevalent variants. The protection of the chimeric vaccine was further verified in macaques. ![]() ![]() Compared with its homotypic forms, the chimeric vaccine elicited broader sera neutralization of variants and conferred better protection in mice. A prototype-Beta chimeric RBD-dimer was first designed to adapt the resistant Beta variant. Here, we developed a chimeric RBD-dimer vaccine approach to adapt SARS-CoV-2 variants. Previously, we developed the protein subunit vaccine ZF2001 based on the dimeric receptor-binding domain (RBD) of prototype SARS-CoV-2. Breakthrough infections by SARS-CoV-2 variants become the global challenge for pandemic control.
0 Comments
Leave a Reply. |